PE20251545A1 - Metodos de purificacion de columna de vector aav - Google Patents

Metodos de purificacion de columna de vector aav

Info

Publication number
PE20251545A1
PE20251545A1 PE2025000717A PE2025000717A PE20251545A1 PE 20251545 A1 PE20251545 A1 PE 20251545A1 PE 2025000717 A PE2025000717 A PE 2025000717A PE 2025000717 A PE2025000717 A PE 2025000717A PE 20251545 A1 PE20251545 A1 PE 20251545A1
Authority
PE
Peru
Prior art keywords
purification methods
aav vector
column purification
chromatography
vector column
Prior art date
Application number
PE2025000717A
Other languages
English (en)
Spanish (es)
Inventor
Younghoon Oh
Guang Qu
Original Assignee
Spark Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spark Therapeutics Inc filed Critical Spark Therapeutics Inc
Publication of PE20251545A1 publication Critical patent/PE20251545A1/es

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D15/00Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08Selective adsorption, e.g. chromatography
    • B01D15/26Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/34Size-selective separation, e.g. size-exclusion chromatography; Gel filtration; Permeation
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D15/00Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08Selective adsorption, e.g. chromatography
    • B01D15/26Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361Ion-exchange
    • B01D15/362Cation-exchange
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D15/00Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08Selective adsorption, e.g. chromatography
    • B01D15/26Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361Ion-exchange
    • B01D15/363Anion-exchange
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151Methods of production or purification of viral material

Landscapes

  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PE2025000717A 2017-06-30 2018-06-29 Metodos de purificacion de columna de vector aav PE20251545A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762527633P 2017-06-30 2017-06-30
US201762531744P 2017-07-12 2017-07-12
US201762567905P 2017-10-04 2017-10-04
PCT/US2018/040430 WO2019006390A1 (en) 2017-06-30 2018-06-29 AAV VECTOR COLUMN PURIFICATION METHOD

Publications (1)

Publication Number Publication Date
PE20251545A1 true PE20251545A1 (es) 2025-06-05

Family

ID=64742749

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2025000717A PE20251545A1 (es) 2017-06-30 2018-06-29 Metodos de purificacion de columna de vector aav
PE2019002713A PE20200737A1 (es) 2017-06-30 2018-06-29 Metodos de purificacion de columna de vector aav

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2019002713A PE20200737A1 (es) 2017-06-30 2018-06-29 Metodos de purificacion de columna de vector aav

Country Status (16)

Country Link
US (1) US20210079422A1 (enExample)
EP (1) EP3658250A4 (enExample)
JP (3) JP2020526190A (enExample)
KR (2) KR102669561B1 (enExample)
CN (1) CN111032176A (enExample)
AU (1) AU2018291023B2 (enExample)
CA (1) CA3068622A1 (enExample)
CL (1) CL2019003915A1 (enExample)
CO (1) CO2020000911A2 (enExample)
IL (1) IL271745A (enExample)
MX (2) MX2020000216A (enExample)
MY (1) MY207534A (enExample)
PE (2) PE20251545A1 (enExample)
PH (1) PH12020500044A1 (enExample)
SG (1) SG11201913157RA (enExample)
WO (1) WO2019006390A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016004113A1 (en) 2014-06-30 2016-01-07 Biogen Ma Inc. Optimized factor ix gene
GB201508026D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Capsid
US12565645B2 (en) * 2019-04-11 2026-03-03 Regenxbio Inc. Methods of size exclusion chromatography for the characterization of recombinant adeno-associated virus compositions
US12403164B2 (en) 2019-09-30 2025-09-02 Bioverativ Therapeutics Inc. Lentiviral vector formulations
AU2021262609A1 (en) 2020-05-01 2022-12-22 Kashiv Biosciences, Llc An improved process of purification of protein
EP3919613B1 (en) * 2020-06-05 2024-08-07 Sartorius BIA Separations d.o.o. Enhanced purification of adeno-associated virus to more effectively remove contaminating dna
KR20230074703A (ko) * 2020-06-24 2023-05-31 바이오버라티브 테라퓨틱스 인크. 유리 인자 viii을 상기 단백질이 발현되도록 변형된 렌티바이러스 벡터의 제제로부터 제거하는 방법
US20220033782A1 (en) * 2020-07-29 2022-02-03 Pall Corporation Adenovirus-associated viruses separation method
EP4229204A1 (en) 2020-10-15 2023-08-23 F. Hoffmann-La Roche AG Nucleic acid constructs for simultaneous gene activation
KR20230085929A (ko) 2020-10-15 2023-06-14 에프. 호프만-라 로슈 아게 Va rna 전사를 위한 핵산 구조체
JP7767029B2 (ja) * 2021-05-28 2025-11-11 ダイセン・メンブレン・システムズ株式会社 細胞外小胞の分離精製方法
JP7716233B2 (ja) * 2021-05-28 2025-07-31 ダイセン・メンブレン・システムズ株式会社 微小有用物質の分離精製方法と分離精製装置
PE20240359A1 (es) * 2021-06-11 2024-02-27 Spark Therapeutics Inc Metodos de purificacion de columna vectorial aav
AU2022358612A1 (en) * 2021-09-28 2024-04-11 Kashiv Biosciences, Llc An improved process of purification of fusion protein
CN114250222A (zh) * 2021-12-08 2022-03-29 苏州博腾生物制药有限公司 一种从动物组织中提取aav dna的方法
GB202117844D0 (en) * 2021-12-09 2022-01-26 Oxford Biomedica Ltd Purification method
JP2023141423A (ja) * 2022-03-24 2023-10-05 国立大学法人 東京大学 ウイルスの精製方法
WO2023198685A1 (en) 2022-04-13 2023-10-19 F. Hoffmann-La Roche Ag Method for determining aav genomes
CN119256220A (zh) 2022-05-23 2025-01-03 豪夫迈·罗氏有限公司 用于区分aav颗粒血清型和aav颗粒荷载状态的基于拉曼的方法
EP4532737A1 (en) 2022-06-03 2025-04-09 F. Hoffmann-La Roche AG Method for producing recombinant aav particles
KR20250036743A (ko) 2022-07-14 2025-03-14 에프. 호프만-라 로슈 아게 재조합 aav 입자를 생산하는 방법
JPWO2024024337A1 (enExample) * 2022-07-28 2024-02-01
EP4744752A1 (en) 2022-09-12 2026-05-20 Hoffmann La Roche METHOD FOR SEPARING SOLID AND EMPTY AAV PARTICLES
EP4385618A1 (en) 2022-12-16 2024-06-19 Chiral Technologies Europe SAS Composite material for bioseparations
IL322001A (en) 2023-02-07 2025-09-01 Hoffmann La Roche Method for detecting antibodies to anti-AAV particles
EP4683676A1 (en) 2023-03-21 2026-01-28 F. Hoffmann-La Roche AG Method for the production of recombinant aav particle preparations
KR20250172636A (ko) * 2023-04-12 2025-12-09 씨티바 바이오프로세스 알&디 에이비 크로마토그래피 시스템, 이의 용도, 및 아데노-연관 캡시드를 분리하는 방법
WO2025168663A1 (en) 2024-02-09 2025-08-14 F. Hoffmann-La Roche Ag Method for producing recombinant adeno-associated viral particles
TW202603164A (zh) * 2024-04-07 2026-01-16 美商星火治療公司 用於腺相關病毒殼體變異體純化之組成物及方法
WO2025252480A1 (en) 2024-06-07 2025-12-11 F. Hoffmann-La Roche Ag Method for purifying plasmid dna
WO2026022064A1 (en) 2024-07-22 2026-01-29 F. Hoffmann-La Roche Ag Novel aav rep orfs and rep polypeptides
WO2026037757A1 (en) 2024-08-13 2026-02-19 F. Hoffmann-La Roche Ag Modified aav particles

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1944362T3 (en) * 1997-09-05 2016-01-25 Genzyme Corp Fremgangsmåder til fremstilling af hjælpevirusfri præparater med høj titer af rekombinante AAV-vektorer
US6593123B1 (en) * 2000-08-07 2003-07-15 Avigen, Inc. Large-scale recombinant adeno-associated virus (rAAV) production and purification
US7261544B2 (en) * 2003-05-21 2007-08-28 Genzyme Corporation Methods for producing preparations of recombinant AAV virions substantially free of empty capsids
KR101812813B1 (ko) * 2009-06-16 2017-12-27 젠자임 코포레이션 재조합 aav 벡터에 대한 개선된 정제 방법
ES2680915T3 (es) * 2010-01-28 2018-09-11 The Children's Hospital Of Philadelphia Plataforma de fabricación escalable para la purificación de vectores virales y vectores virales purificados de este modo para su utilización en terapia génica
MX2018006682A (es) * 2015-12-01 2018-09-26 Spark Therapeutics Inc Metodos escalables para producir vector viral adenoasociado (aav) recombinante en un sistema de cultivo celular en suspension libre de suero adecuado para su uso clinico.
US11015173B2 (en) * 2015-12-11 2021-05-25 The Trustees Of The University Of Pennsylvania Scalable purification method for AAV1
ES2918998T3 (es) * 2015-12-11 2022-07-21 Univ Pennsylvania Método de purificación escalable para AAVrh10
WO2017100676A1 (en) * 2015-12-11 2017-06-15 The Trustees Of The University Of Pennsylvania Scalable purification method for aav8
ES2896080T3 (es) * 2016-03-31 2022-02-23 Spark Therapeutics Inc Procedimiento en columna totalmente escalable de preparación de VAAr

Also Published As

Publication number Publication date
WO2019006390A1 (en) 2019-01-03
EP3658250A4 (en) 2021-10-27
JP2023029832A (ja) 2023-03-07
JP2025038906A (ja) 2025-03-19
CL2019003915A1 (es) 2020-06-19
KR102879640B1 (ko) 2025-10-30
MX2024007103A (es) 2024-06-24
MY207534A (en) 2025-03-03
KR20240093848A (ko) 2024-06-24
BR112019028299A2 (pt) 2020-07-14
CO2020000911A2 (es) 2020-06-19
MX2020000216A (es) 2020-09-03
CN111032176A (zh) 2020-04-17
AU2018291023B2 (en) 2023-11-02
EP3658250A1 (en) 2020-06-03
KR20200040749A (ko) 2020-04-20
PH12020500044A1 (en) 2020-09-14
JP2020526190A (ja) 2020-08-31
US20210079422A1 (en) 2021-03-18
KR102669561B1 (ko) 2024-05-24
SG11201913157RA (en) 2020-01-30
IL271745A (en) 2020-02-27
CA3068622A1 (en) 2019-01-03
RU2020103743A (ru) 2021-07-30
RU2020103743A3 (enExample) 2021-09-30
AU2018291023A1 (en) 2020-02-06
PE20200737A1 (es) 2020-07-23

Similar Documents

Publication Publication Date Title
PE20200737A1 (es) Metodos de purificacion de columna de vector aav
IL279193A (en) Anion exchange chromatography for recombinant AAV production
EP3387137A4 (en) TARGET PEPTIDES FOR LEADING ADENO ASSOCIATED VIRUSES (AAVS)
EP3645021A4 (en) ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
DK3294323T3 (da) Adeno-associeret virus til terapeutisk indgivelse til centralnervesystemet
SI3256573T1 (sl) Čiščenje delca rekombinantnega adeno-povezanega virusa z več-koračno anion-izmenjevalno kromatografijo
PT3723783T (pt) Péptidos dirigidos à mitocôndria
EP3491149A4 (en) INDEPENDENT NUCLEIC ACID PROCESSING
DK3538559T3 (da) Rekombinante pmhc klasse ii-molekyler
CL2019000033A1 (es) Variantes de xilanasa y polinucleótidos que las codifican.
WO2018005867A3 (en) Structure-based peptide inhibitors of alpha-synuclein aggregation
EP3481853A4 (en) Genetic perturbation of the rna degradosome protein complex
BR112017011226A2 (pt) peptídeo, composição farmacêutica, processo para fabricação da composição farmacêutica
MX382218B (es) Variantes de lipasa y polinucleotidos que las codifican.
BR112017015721A2 (pt) expressão induzida de fator neurotrófico derivado do cérebro (bdnf) para o tratamento de doenças neuromusculares, neurodegenerativas, autoimunes, do desenvolvimento e/ou metabólicas.
PH12019501064A1 (en) Ras PROTIEIN DEGRADATION INDUCING MOLECULE AND PHARMACEUTICAL COMPOSITION
EP3385581A4 (en) SHUT-OFF VALVE WITH PLATE REPLACEMENT STRUCTURE
BR112016022575A2 (pt) Composições e métodos para o tratamento de doenças neurodegenerativas
EP4387750A4 (en) ANION EXCHANGE CHROMATOGRAPHY METHODS FOR THE PURIFICATION OF RECOMBINATING ADENO-ASSOCIATED VIRUSES
MX2019001804A (es) Peptidos modificados para uso en el tratamiento de trastornos neurodegenerativos.
DK3271374T3 (da) Peptid som binder specifikt til en a-beta-species til terapi og/eller diagnosticering af alzheimers demens
EP3538657A4 (en) CYTOCHROME B (CYTB) NUCLEIC ACID MOLECULES FOR THE CONTROL OF PATHOGENS
EP3351251A4 (en) Nucleic Acid MOLECULE
EP3393524A4 (en) PROTECTION OF RNAS FROM DEGRADATION BY MEANS OF VIRUS RNAS
TH180403A (th) "องค์ประกอบปรับสภาพเส้นผมที่ประกอบรวมด้วยสวิทเทอร์ไอออน หรือวัสดุที่เป็นโปรตีน"